Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATON: Aflibercept T&E for BRVO Macular Edema
NCT03405376Phase 4Unknown
- Sponsor
- Yeungnam University College of Medicine
- Start
- Jan 2018
- Primary completion
- Mar 2019
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in macular edema, sponsored by Yeungnam University College of Medicine. Primary endpoint: Mean change of best corrected visual acuity at 72 weeks. Status: unknown.
02
Drugs
aflibercept
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT03405376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03405376.